What We’ve Learned in 9 Years.

Walk into any pharmacy and the probiotic shelf makes a hundred promises. Walk into a clinic and you’ll find most providers quietly skeptical — not because they doubt the microbiome matters, but because they couldn’t answer the only question that counts at the point of care: will this work for the person in front of me?

We started in 2015 with a different idea: don’t guess from strain claims in unrelated studies. Sequence the patient, formulate against what their microbiome actually shows, and — this is the part almost nobody does — follow up. Record what happened. Do it again, for nine years, across thousands of patients. Pair the before with the after.

That dataset is now big enough, and longitudinal enough, to say something real. So we’re saying it.

It means the answer to “will this work for my patient?” is no longer a shrug. When you submit a patient’s microbiome data, we can match it against the patients who looked like them and the formulations that resolved their symptoms. Resolution rates run from 45.2% (anxiety) to 65.0% (depression) by first follow-up, climbing as patients stay the course. And because 20.4% of patients present across two or more body systems, the data also validates layering and multi-formula recommendations rather than forcing one blunt product.

This is real-world, observational evidence — we’re explicit about its limits below. But it’s evidence that exists, at a scale no one else in this category can show, and it’s the foundation under every formulation Flore Clinical generates.

We’re putting our work out for scrutiny.

Confidence in medicine is earned through transparency. We’re sharing the findings, publishing the methods, and inviting MDs, researchers, and academic partners to review the white paper and challenge the work — including the RCTs now underway for The Regular One and The Bright One.